...
首页> 外文期刊>Clinical journal of the American Society of Nephrology: CJASN >Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist
【24h】

Predictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist

机译:内皮素受体拮抗剂治疗后充血性心力衰竭的预测因子

获取原文

摘要

Background and objectives The Avosentan on Time to Doubling of Serum Creatinine, End Stage Renal Disease or Death (ASCEND) trial tested the renoprotective effect of the endothelin receptor antagonist avosentan in patients with diabetes and nephropathy, but the study was terminated due to an excess of congestive heart failure (CHF) events in the avosentan arms, likely due to fluid retention. The aim of this study was to identify risk markers of CHF after treatment with avosentan.
机译:背景和目的Avosentan在使血清肌酐,终末期肾脏疾病或死亡倍增的时间(ASCEND)试验测试了内皮素受体拮抗剂avosentan对糖尿病和肾病患者的肾脏保护作用,但由于过量阿伏生坦组的充血性心力衰竭(CHF)事件,可能是由于液体retention留所致。这项研究的目的是确定用阿伏生坦治疗后的CHF危险标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号